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Abstract
Positron emission tomography (PET) imaging of the 18 kDa translocator protein (TSPO), which is upregulated in activated
microglia, is a method for investigating whether immune activation is evident in the brain of adults with schizophrenia. This
study aimed to measure TSPO availability in the largest patient group to date, and to compare it between patients with recent
onset (ROS) and established (ES) schizophrenia. In total, 20 ROS patients (14 male), 21 ES (13 male), and 21 healthy
controls completed the study. Patients were predominantly antipsychotic-medicated. Participants underwent a PET scan
using the TSPO-specific radioligand [11C](R)-PK11195. The primary outcome was binding potential (BPND) in the anterior
cingulate cortex (ACC). Secondary outcomes were BPND in six other regions. Correlations were investigated between TSPO
availability and symptom severity. Data showed that mean BPND was higher in older (ES and controls) compared with
younger (ROS and controls) individuals, but did not significantly differ between ROS or ES and their respective age-
matched controls (ACC; ANOVA main effect of diagnosis: F1,58= 0.407, p= 0.526). Compared with controls, BPND was
lower in antipsychotic-free (n= 6), but not in medicated, ROS patients. BPND in the ES group was negatively correlated with
positive symptoms, and positively correlated with negative symptom score. Our data suggest ageing is associated with
higher TSPO but a diagnosis of schizophrenia is not. Rather, subnormal TSPO levels in drug-free recent-onset patients may
imply impaired microglial development and/or function, which is counteracted by antipsychotic treatment. The development
of novel radioligands for specific immune-mechanisms is needed for further clarification.
Introduction
Several lines of evidence suggest that immune activation
and inflammation play a role in the pathophysiology of
schizophrenia. For example, meta-analyses report increased
blood levels of c-reactive protein, IL-6 and a range of other
cytokines compared with non-patients and some changes
normalise with recovery [1, 2]. However, increases are
rarely in the pathological range, and conventional anti-
inflammatory drugs such as aspirin have limited efficacy.
In the last decade, it has become possible to investigate
inflammation in the living human using positron emission
tomography (PET) in various neurodegenerative disorders.
Microglia are the resident macrophages of the central ner-
vous system (CNS) [3]. In their activated immune state,
microglia secrete cytokines and chemokines and this is
associated with increased expression of the translocator
protein (TSPO) for which a number of radioligands have
been developed.
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Early studies reported increased brain TSPO expression
in schizophrenia, suggesting the presence of microglial
activation and neuroinflammation [4, 5]. These studies
motivated our initial PET study using [11C](R)-PK11195,
which found no difference in TSPO expression between
medication-free schizophrenia patients and matched healthy
subjects [6]. Most other studies have reported unchanged
or decreased TSPO expression [6–13]. Indeed, a recent
meta-analysis of five studies concluded that PET TSPO
radioligand binding is statistically significantly reduced
in recent onset schizophrenia unrelated to treatment
status [14].
In the present study, we aimed to compare TSPO
expression between (i) schizophrenia patients with recent
onset of symptoms (ROS group); (ii) an established illness
group with at least 10 years of symptoms (ES group); and
(iii) healthy controls using [11C](R)-PK11195 PET in order
to determine differences across illness stages and to get a
more conclusive answer regarding a potential role of
microglial activation in schizophrenia. The primary region
of interest (ROI) was the anterior cingulate cortex (ACC),
based on evidence of grey matter loss [15] and increased
glutamate content in ACC [16]. Secondary ROIs were based
on our previous research [6] and included the prefrontal
cortex (PFC), orbitofrontal cortex (OFC), parietal cortex,




In total, 20 recent onset patients (14 males; mean ± standard
deviation [SD]: 24.2 ± 5.1 years); 21 established patients
(13 males; mean ± SD: 46.0 ± 6.0 years); and 21 age- and
sex-matched controls: 10 matched to recent onset (8 males;
mean ± SD: 25.5 ± 4.1 years), 11 matched to established
patients (7 males; mean ± SD: 47.0 ± 5.0 years) completed
the study. It was calculated that a study sample size of 20
participants in each group could detect a between-group
difference in binding potential (BPND) of 15%, with a power
of 80%, α= 0.05, two-sided. Patients met DSM-IV criteria
for schizophrenia, schizoaffective disorder or schizo-
phreniform disorder (all referred to in the paper as “schi-
zophrenia”), as determined by consensus of two clinicians
(CG, PST, and/or BD) following case note review and
patient interview.
Inclusion criteria for recent onset patients were: <5 years
from onset and <12 weeks lifetime exposure to anti-
psychotic medication, and for established patients >10 years
from onset and no major changes to antipsychotic medica-
tion over the previous 8 weeks. Controls were age- and sex-
matched to patients and included if they had no personal or
first-degree relative with a history of psychosis, or a history
of depression within the past two years. We excluded par-
ticipants who: had significant physical illness such as an
inflammatory or neurological condition; were taking anti-
inflammatory medication; and who met DSM-IV criteria for
harmful use of substances within the past month or
dependence within the past 6 months. Females could not
participate when pregnant or breast-feeding.
For patients, symptom severity was assessed on the day
of scanning using the Positive and Negative Syndrome
Scale (PANSS) [17] and level of functioning by the Per-
sonal and Social Performance Scale (PSP) [18]. Scales were
administered and scored by a trained clinician (CG).
The present study was conducted at the University of
Manchester (UoM), as part of a multi-centre multi-modal
imaging project (the SPRING study) that was conducted at
UoM, the University of Nottingham and Cardiff University.
The study was approved by the North-West Lancaster
National Research Ethics Service Committee and the United
Kingdom Administration of Radioactive Substances Advi-
sory Committee, and was carried out in compliance with the
Declaration of Helsinki (1964), amended in Edinburgh
(2000). Participants gave their written informed consent
prior to study participation.
Image acquisition
Image acquisition and analysis methodology for this study
was similar to recent publications from our group [6, 19]. In
summary, a high-resolution T1-weighted magnetic reso-
nance (MR) image was acquired for data-processing, iden-
tification of ROIs, and voxel-based morphometry analysis
using a 3T Philips Achieva scanner. PET imaging was
performed using a High-Resolution Research Tomograph
(Siemens). For each PET scan, following a 6 minute trans-
mission scan, [11C](R)-PK11195 was intravenously injected
with a target dose of 740MBq. Dynamic emission data were
acquired for 60 min. The data was re-binned into 18 frames
of variable duration and reconstructed.
Image processing
A summation image was created and co-registered with the
T1-weighted MR image using Vinci version 2.55 (Max-
Planck Institute for Neurological Research, Cologne, Ger-
many), segmented into grey and white matter using SPM8
(Statistical Parametric Mapping, Wellcome Department of
Imaging Neuroscience, Institute of Neurology, London,
UK), and normalised using the n30r83 version of the
probabilistic brain-atlas by Hammers et al. [20].
A binary grey matter mask was created in Vinci using a
threshold of 0.5. Object maps (standardised anatomical
areas) were defined using Analyze 11.0 (BIR, Mayo Clinic,
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Rochester, MN). Parametric images of BPND were created
using MICKpm 5.2 (in-house MATLAB based software),
using the simplified reference tissue model and the time
activity curve from the bilateral grey matter cerebellum as
reference tissue input function. BPND for each ROI were
read out from the parametric maps by applying the
object maps.
Statistical analysis
We used SPSS Statistics Version 22 (IBM, Armonk, NY,
USA). Data were analysed by SC, CG, and RH. Differences
in demographic and clinical characteristics between groups
were assessed using independent samples t-tests (2-sided),
chi-square test of homogeneity or Fisher’s exact test (two-
sided). Between-group differences in BPND in the ACC
were assessed using a two-way ANOVA with diagnosis
(patients and controls) and age (younger and older) as fixed
factors. Between-group differences in BPND in all ROIs (the
secondary ROIs) were assessed using repeated-measures
ANOVA with brain region (ACC, PFC, OFC, parietal
cortex, putamen, thalamus, and brainstem) as the within-
subjects factor. The effect size of between-group differences
in BPND was calculated as Cohen’s d (the difference
between the means divided by the pooled standard
deviation).
Shapiro-Wilk’s test and visual inspection of Q-Q plots
was done to assess normal distribution and possible outliers.
Box’s test was done to assess equality of covariance,
Levine’s test to assess homogeneity of variances, and
Mauchly’s test to assess sphericity of the data using the
Greenhouse-Geisser correction if violated. Differences in
individual ROIs were assessed post hoc in an exploratory
fashion using independent samples t-tests.
Correlation of regional BPND with PANSS and PSP
scores were assessed using Pearson’s r, or Spearman’s
coefficients if a measure was not normally distributed.
Findings were considered significant at the p < 0.05
(2-sided) level.
Results
Demographic and clinical characteristics for all participants
are outlined in Table 1. An overview of psychotropic
medication of the patient groups can be found in the sup-
plement, Tables S1 and S2. Patients and controls were well
matched with no significant differences between them in
age, sex, BMI or injected mass of [11C](R)-PK11195. A
greater proportion of patients were smokers compared with
controls. There were no significant differences between
recent onset and established patients in PANSS scores, PSP
scores, sex or smoking status (Table 1). Established patients
had a significantly higher BMI than recent onset patients
and, by design, established patients were older and had a
significantly longer duration of illness. There was no dif-
ference between the patient groups in antidepressant usage.
Combining all patients and all controls there was no main
effect of sex, BMI, smoking status or injected mass of [11C]
(R)-PK11195 so these were not included as covariates.
Mean BPND for caudate, amygdala, hippocampus and
temporal cortex was around zero (see Supplementary
Table 1 Demographic and
clinical characteristics of
participants.










Sex (M) 8 (80%) 14 (70%) – 7 (64%) 13 (62%) – –
Age (years) 25.5 ± 4.1 24.2 ± 5.1 0.48 46.7 ± 4.8 46.3 ± 6.4 0.85 0.000*
BMI (kg/m2) 26.5 ± 3.6 24.7 ± 3.6 0.19 26.6 ± 5.2 29.5 ± 5.3 0.15 0.002*
Smoking (Yes) 4 (40%) 17 (85%) – 2 (18%) 15 (71%) – –
Duration of illness
(months)
– 16 ± 17 – – 249 ± 88 – 0.000*
PANSS total – 57 ± 12 – – 55 ± 13 – 0.74
PANSS positive – 15 ± 6 – – 15 ± 7 – 0.92
PANSS negative – 12 ± 4 – – 13 ± 5 – 0.53
PANSS general – 30 ± 6 – – 27 ± 6 – 0.22
PSP – 59 ± 14 – – 53 ± 15 – 0.14
Injected mass of
PK11195 (μg)
1.39 ± 0.63 1.86 ± 1.72 0.29 1.28 ± 0.66 1.22 ± 0.91 0.84 0.15
Values are presented as mean ± SD.
BMI body mass index, PANSS positive and negative syndrome scale, PSP personal and social
performance scale.
*Significant difference between groups at p ≤ 0.05.
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Fig. S1) and these regions were therefore not included in
subsequent analyses. The primary dependent variable was
BPND in the ACC.
Furthermore, in the supplementary material, data is pre-
sented of exploratory post hoc analyses that were carried
out to test the significance of any difference in BPND in
individual ROIs between our patient groups and matched
controls, and to establish any main effect of age or age X
diagnosis interaction (Supplementary Table S3, Fig. S2, and
Table S4).
Visual inspection of the data showed that BPND in the
ACC was similar between each patient group and its
respective control group (Fig. 1a). BPND was greater in
established patients and their controls compared with the
younger group of recent onset patients and controls. Two-
way ANOVA showed no significant difference in BPND
between patients and controls (no main effect of diagnosis;
F1,58= 0.41, p= 0.53). There was a significant main effect
of age (F1,58= 15.49, p < 0.001) but no significant age*-
diagnosis interaction (F1,58= 0.59, p= 0.45).
Statistical effects of age and diagnosis were similar to
ACC across all 7 ROIs (Fig. 1b) with no main effect of
diagnosis (F1,58= 1.45, p= 0.23), a main effect of age
(F1,58= 7.05, p= 0.01), and no significant age*diagnosis
interaction (F1,58= 0.13, p= 0.72). However, there was a
significant ROI*diagnosis interaction (F3.152,182.787= 2.97,
p= 0.03) due to statistically significant overall reductions in
putamen and thalamus in patients compared with controls
(Supplementary Fig. S3 and Table S5). The ROI*diagno-
sis*age interaction was not significant (F3.152,182.78= 1.90,
p= 0.13).
Patients with recent onset schizophrenia who were
antipsychotic-free (n= 6) were compared with those who
were currently taking an antipsychotic (n= 14; an overview
of their patient characteristics and the matched controls
characteristics can be found in Supplementary Table S6).
Mean BPND across all ROIs combined was lower in
antipsychotic-free patients compared with controls (Fig. 2,
Table 2) producing a statistically significant main effect of
group (F1,14= 5.26, p= 0.04). There was no region*group
interaction (F(2.043,28.604)= 0.27, p= 0.77). The data for
individual ROIs (Table 2) showed that BPND was lower in
antipsychotic-free patients compared with controls, with
medium (≥0.5) or large (≥0.8) effect sizes in all ROIs. There
were no statistical differences in BPND between
antipsychotic-exposed patients and their recent onset con-
trols (Supplementary Table S7), or between antipsychotic-
free and exposed recent-onset patients (Supplementary
Fig. S4 and Table S8). Except in the brainstem, where BPND
was higher in antipsychotic-exposed compared with
antipsychotic-free patients.
Fig. 1 Mean [11C](R)-PK11195




potential is compared with age
and sex-matched controls in the
anterior cingulate cortex (ACC;
[a]) and in all regions of interest
(ROIs) together (i.e., ACC, PFC,
OFC, parietal cortex, putamen,
thalamus and brainstem; [b]).
Orange symbols represent
female participants. Black lines
in scatterplot indicate mean ±
SEM per group.
Fig. 2 Mean [11C](R)-PK11195 BPND in antipsychotic-free recent
onset schizophrenia (Sz) patients. Patient binding potential is com-
pared with age and sex-matched controls in all regions of interests
combined (ROIs). Orange symbols represent female participants.
Black lines in scatterplot indicate mean ± SEM per group.
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In the established patients, there was a moderate negative
correlation between PANSS positive score and [11C](R)-
PK11195 BPND in all ROIs except in the brainstem,
reaching significance in the ACC, PFC, OFC and putamen
(Supplementary Table S9). In contrast, PANSS negative
scores positively correlated with BPND in all ROIs, reaching
significance in the PFC and OFC. Figure 3 presents the
correlation of PANSS positive and negative scores in
the OCC, which showed the strongest correlation, and in the
ACC, the primary ROI. PANSS general and total scores and
the PSP did not correlate with BPND in any region
(Supplementary Table S9). The correlation between BPND
and clinical measures in patients with recent onset schizo-
phrenia and all patients with schizophrenia can be found in
the supplement, Tables S10 and S11, respectively.
A voxel-based morphometry analysis using SPM12 was
carried out on the T1-weighted MR images to examine
potential differences in grey matter volume between schi-
zophrenia patients and controls. No significant between-
group grey matter volume differences were found, sug-
gesting that the significant differences in BPND in our data
are unlikely to be an artefact of differences in regional tissue




with age- and sex-matched
healthy controls.
Controls (n= 10) Antipsychotic-free
patients (n= 6)
Controls vs Antipsychotic-free
Region BPND BPND Difference (%) Cohen’s d
ACC 0.086 ± 0.038 0.036 ± 0.073 −58 0.86
PFC 0.058 ± 0.042 0.024 ± 0.071 −59 0.58
OFC 0.039 ± 0.035 0.0003 ± 0.064 −99 0.75
Parietal 0.044 ± 0.041 0.020 ± 0.052 −55 0.51
Putamen 0.075 ± 0.047 0.018 ± 0.042 −76 1.28
Thalamus 0.196 ± 0.063 0.144 ± 0.077 −27 0.74
Brainstem 0.142 ± 0.061 0.097 ± 0.058 −32 0.76
Mean all ROIs 0.092 ± 0.030 0.048 ± 0.046 −48 1.13
BPND values are presented as mean ± SD.
BPND binding potential, ROI region of interest, ACC anterior cingulate cortex, PFC prefrontal cortex, OFC
orbitofrontal cortex.
Fig. 3 Correlation of Positive
and Negative Syndrome Scale





(BPND) and scores on the
positive (a) and negative (b)
subscales of the PANSS in the
orbitofrontal cortex (OFC), and
scores on the positive (c) and
negative (d) subscales of the
PANSS in the anterior cingulate
cortex (ACC) across established
schizophrenia patients, divided
into male and female
participants.
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volumes. For details of the VBM methodology, please see
Holmes et al. [19].
Discussion
The present study was conducted to determine whether
there are differences in regional brain TSPO expression, an
indication of microglial activation, across schizophrenia
illness stages, and is the largest PET study to investigate
potential microglial activation in schizophrenia to date. In
the ACC, the primary ROI, there was no main effect of
diagnosis and neither the recent onset nor the established
group differed from their respective controls in [11C](R)-
PK11195 BPND. Similarly there was no main effect of
group across all 7 ROIs (i.e., ACC, PFC, PFC, parietal
cortex, putamen, thalamus and brainstem) but 2 ROIs dif-
fered significantly from the others; in the thalamus and
putamen, [11C](R)-PK11195 binding was reduced in the
total sample of 40 patients compared with the 20 controls.
There was an increase in the older clinical and control
groups compared with the younger groups, in line with a
previous study using TSPO radioligand [11C]PBR28 [21].
The recent onset group tended to have reduced [11C](R)-
PK11195 binding compared with their controls and the
reduction was statistically significant in the 6 patients who
were not receiving antipsychotics. This pattern of results
was repeated in the 6 other secondary cortical and sub-
cortical ROIs in the recent onset patients.
Our study has several limitations. [11C](R)-PK11195 has
a relatively poor signal to noise ratio [22] which limits the
ability to detect small changes in TSPO binding as might
occur in a low level inflammatory condition like schizo-
phrenia. Nevertheless, this does not account for the sig-
nificant reduction in binding seen in antipsychotic-free
patients. The choice of radioligand and analytic methods are
discussed in the supplementary material. Having a patient
population comprising of schizophrenia, schizoaffective and
schizophreniform disorder may contribute to heterogeneity.
Currently, there is however no detailed knowledge about
neurological differences between these patient groups and
we therefore decided not to differentiate between them.
Furthermore, clinically significant depressive symptoms
might have introduced a tendency towards elevated [11C]
(R)-PK11195 BPND as shown in previous studies in major
depressive disorder [19], yet we did not assess depressive
symptoms by means of depression scales. Our results
however indicate an absence of increased PET TSPO
binding in patients, suggesting no increase was caused by
potential depression comorbidity. Our study included rela-
tively few antipsychotic-free patients (n= 6), of whom only
two were antipsychotic-naïve. Although all our patients
with recent onset schizophrenia had <12 weeks exposure to
antipsychotics, our results suggest that even minimal
exposure to antipsychotics may have an influence on BPND.
Established patients had a long history of exposure to
antipsychotic medication, making it difficult to draw firm
conclusions about the effects of illness duration. Our
patients were also mainly stable with mild symptom
severity, limiting the ability to detect correlations between
severity and BPND. It is possible that increased TSPO
expression can be found in the prodrome or at the onset of
symptoms or in those with treatment resistant schizo-
phrenia. Finally, our study was not designed or powered to
investigate between-sex differences in BPND. Visual
inspection of Fig. 2, in which antipsychotic-free recent
onset patients show significantly lower BPND than matched
younger controls, suggests that this difference is driven by
the male patients. However, the very small number of
females in each group (n= 2) makes it impossible to draw
clear conclusions and future studies could investigate this
possibility further.
We did not find evidence of increased microglial acti-
vation in recent onset patients with minimal (<12 weeks) or
no exposure to antipsychotic drugs. The results are in
keeping with the majority of previous studies [8–13] also
showing no TSPO difference between patients and controls,
and a recent post-mortem study showing no increase in
TSPO in brain tissue of schizophrenia patients [23]. One
major study reported increased [11C]PBR28 TSPO binding
in people with ultra-high risk for psychosis and with early
psychosis [24]. However, the analysis method has been
challenged [25]. The data were included in a recent meta-
analysis that found no increase in TSPO binding in schi-
zophrenia regardless of disease stage, but on the contrary
found strong evidence for reductions that were unrelated to
drug treatment [14]. In the present study, we found that
BPND was lower in antipsychotic-free recent onset patients
across all ROIs compared with matched controls as have
other studies [7, 9, 10]. This may potentially reflect a
chronic neurodevelopmental abnormality of microglial
function in schizophrenia. It is therefore possible that TSPO
availability does not accurately reflect low level inflamma-
tion in schizophrenia, or that it reflects a reduced ability by
the immune system to mount an anti-inflammatory
response. Recent studies report promising PET tracers
for the quantification of mitochondrial and synaptic func-
tion, which in the future might be preferable over TSPO
tracers [26].
We also found reduction in all patients compared with
controls in the putamen and thalamus in the entire sample.
Our findings therefore add to an emerging body of evidence
that TSPO availability is reduced in the early years of
psychosis and possibly especially apparent in drug-free
patients. The fact that reduced BPND was also associated
with greater PANSS positive symptom scores in those with
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many years of illness suggests reduced BPND could be a
marker close to an underlying pathogenic mechanism of
psychosis.
Reduced TSPO binding in schizophrenia stands in con-
trast to increases in PET TSPO binding reported in several
CNS inflammatory disorders with known pathologies
involving microglial activation including stroke, multiple
sclerosis, and Alzheimer’s and Huntington’s diseases. Fur-
thermore, we and one other group have recently reported
increases in [11C](R)-PK11195 binding in patients with
major depression which is associated with mild increases in
systemic immune signalling although not with gross CNS
inflammatory pathology [19, 27]. Nevertheless, the anti-
microglial anti-inflammatory antibiotic, minocycline
showed evidence of efficacy in depression in two clinical
trials (see [28]), suggesting the raised PET TSPO binding
could reflect a causal inflammatory process and possibly
microgliosis. In contrast, minocycline was of no benefit in a
recent major clinical trial in recent onset schizophrenia,
in keeping with the absence of increased PET TSPO
binding [28].
A neuroinflammatory process is however not ruled out
by the present results. For example, in an infection-
mediated neurodevelopmental mouse model of schizo-
phrenia, behavioural abnormalities were associated with
raised cytokine concentrations in the PFC but with reduced
prefrontal TSPO concentrations with no microglial activa-
tion [29]. Furthermore, much of the evidence that inflamed
microglia produce increased TSPO expression comes from
in vitro rodent studies, but there is evidence that human and
rodent microglia may respond differently to immune acti-
vation in vitro [30]. Indeed, three recent expression-
profiling studies in several post-mortem brain datasets,
report no evidence of increased microglial patterns of gene-
expression in schizophrenia [31–33]. The same studies do,
however, report increased astroglial gene expression which
could mediate neuronal dysfunction in schizophrenia.
Importantly for the present discussion, it is known that
astroglia are a principle source of transforming growth
factor β in the brain, which has potent effects in shifting
microglia into their non-amoeboid phenotype associated
with their important role in synaptic remodelling [34–36].
Reduced TSPO binding in schizophrenia could thus reflect
an increase in the proportion of microglia that are in a low
TSPO-expressing synaptic housekeeping state; this shift
could be a cause or an effect of the recent evidence for an
old hypothesis that excessive synaptic elimination occurs in
schizophrenia [37, 38].
Recent onset patients on medication showed no reduc-
tions in BPND and this could reflect a normalisation of the
process causing the reduction in the drug-free patients or a
pro-inflammatory effect of the drugs. There is little evidence
of pro-inflammatory effects of antipsychotic drugs in terms
of cytokine levels in brains from treated animals or in
clinical populations. In the current study, neither lifetime
exposure to medication nor current exposure correlated
with BPND or symptom ratings (data not shown) but the
selection criteria resulted in little variation in treatment
exposure within the two clinical groups. In the established
group greater BPND correlated with greater negative
symptom scores as in our previous study [6]. But lower
BPND values were associated with positive symptoms.
Positive and negative symptom ratings were, as expected,
orthogonal (r= 0.02, n= 41). The findings imply that the
two syndromes have an independent pathogenesis which
bear an opposite relationship with TSPO expression. The
outcome of these two independent processes (the ratio of
positive to negative symptoms) determined a remarkable
27–40% of the variance in observed BPND in the three
cortical regions.
In conclusion, we report that schizophrenia is not asso-
ciated with microglial activation as measured by TSPO
expression in the early or established phases of the illness.
Indeed, reduced TSPO expression was seen in the putamen
and thalamus, in antipsychotic-free recent onset patients and
in association with positive symptoms in established illness.
The results add to a growing body of evidence that reduced
TSPO availability may reflect an important aspect of
pathogenesis. However, understanding this signal requires
the development of PET tracers for the different molecular
and cellular components of neuroinflammation that con-
verge to produce the pattern of TSPO expression reported in
schizophrenia.
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